#immunotherapy

Targeted therapies are available for eight tumor mutations, highlighting the importance of genomic testing.

The antibody-drug conjugate Tivdak led to remission in 24% of cervical cancer patients.

Many older people have biomarkers indicative of a strong response to checkpoint inhibitors.

The immune system has a natural ability to shut down cells that grow out of control, but cancer has many ways to get around these defenses.

Early treatment is linked to a smaller viral reservoir, but blocking IL-10 and PD-1 might control the virus in those with chronic infection.

Some people with blood cancers, however, may not be as well protected.

An oncolytic virus that kills cancer cells and triggers immune responses against tumors shows promise for children with brain cancer.

The coronavirus vaccines are safe and should be effective even for people with advanced cancer.

A checkpoint inhibitor combination and an antibody-drug conjugate may offer new treatment options.

The report highlights how cancer research is extending and improving lives and includes a special feature on COVID-19 and cancer challenges.

Through her sculptures, Shelley Kerr describes the battle, journey and gratitude of living with stage IV bladder cancer.

Cancer-fighting T cells led to complete or partial tumor remission in at least 25% of lung cancer patients.

Edited T cells survive and thrive in three patients in the first U.S. trial using this approach.

Customized treatments demonstrate good response rates for mantle cell lymphoma and chronic lymphocytic leukemia.

Space travel and chemotherapy affect the body similarly, and yet only astronauts undergo physical conditioning to help them stay strong.